(Total Views: 891)
Posted On: 05/05/2017 12:50:10 PM
Post# of 72447
Pinch this puppy next week. On deck, prurisol interim data and more brilacidin data.
Let's see. Another company (MotifBio) recently pushed to around $10 (topped at $11) with an O/S of 195,741,528 as of December 31, 2016. CTIX has an O/S of 126,408,756. This was on a P3 result for ABSSSI with revive-1. From what we know about brilacidin would beat them hands down on delivery and reaction time.
The 2 current trials for brilacidin will pave the way imo. And Prurisol will help pay for it.
All IMO.
Let's see. Another company (MotifBio) recently pushed to around $10 (topped at $11) with an O/S of 195,741,528 as of December 31, 2016. CTIX has an O/S of 126,408,756. This was on a P3 result for ABSSSI with revive-1. From what we know about brilacidin would beat them hands down on delivery and reaction time.
The 2 current trials for brilacidin will pave the way imo. And Prurisol will help pay for it.
All IMO.
(3)
(0)
